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Abstract
Background: Rubinstein-Taybi syndrome (RSTS; OMIM #180849, #613684) is a rare autosomal dominant genetic
condition characterized by broad thumbs and halluces, facial dysmorphism, short stature and variable degree of
intellectual disability. RSTS is associated with mutations in CREBBP and EP300 genes in 50–60% and 5–8% of cases,
respectively. The majority of cases are de novo heterozygous mutations.
Case presentation: Here we describe a familial RSTS case, associated with a novel EP300 mutation. The proband was
a 9 years old female, with mild learning difficulties. Her mother, who also had learning difficulties, was found to have
short and broad thumbs. MLPA and panel-based NGS of CREBBP and EP300 were performed. A novel heterozygous
frameshift mutation in exon 31 of the EP300 gene (c.7222_7223del; p.(Gln2408Glufs*39)) was found in both.
Conclusions: This case represents the first case of inherited EP300-RSTS. The location of the frameshift deletion not
affecting HAT domain and PHD finger, could explain the mild phenotype and the well-preserved intelligence. These
patients are mildly affected, and this case highlights the possible missed diagnosis. We would recommend molecular
testing of apparently healthy parents, and in the case of inherited mutations, of all adult first degree relatives at risk.
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Background
Rubinstein-Taybi syndrome (RSTS; OMIM #180849,
#613684) is a rare (1:125000) complex neurodevelop-
mental disorder characterized by broad thumbs and hal-
luces, facial abnormalities (downslanted palpebral
fissures, low hanging columella, high palate, grimacing
smile, and talon cusps), postnatal growth delay and intel-
lectual disability (ID) [2, 10]. In addition, RSTS patients
have a slightly increased predisposition to cancer [9].
RSTS is an autosomal dominant condition and the vast
majority of cases occur sporadically due to de novo het-
erozygous mutations, being vertical transmission ex-
tremely rare [7]. So far, Bartsch et al. [3] described only
five familial cases of RSTS, consistent with autosomal
dominant inheritance, and recently another possible case
has been described in India [15].
Two genes have been implicated with RSTS: CREBBP,
located on chromosome 16p13.3, encoding a CREB-
binding protein (CBP), and EP300, which maps to
22q13.2 and encodes E1A-associated protein p300. They
are very similar and function as transcriptional coactiva-
tors in the regulation of gene expression mediating many
of the same signalling pathways. CBP and p300 are
highly conserved and have potent histone acetyltransfer-
ase (HAT) activity. Consequently, there is a direct link
between loss of acetyltransferase activity and RSTS sug-
gesting an aberrant chromatin regulation [17, 18]. Des-
pite their high sequence similarity (>70%), CBP and
p300 have differences in their respective functions [1].
RSTS is caused in approximately 50–60% of cases by
mutations of the CREBBP gene (RSTS 1, OMIM
#180849), and by EP300 gene mutations (RSTS 2,
OMIM #613684) in 5–8%. To date, 246 disease causing
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mutations in the CREBBP gene have been reported to
cause RSTS [7]. In contrast, only 23 RSTS patients with
EP300 mutations, and a total of 34 mutations, have been
described in this gene [10, 14]. The mutations described
in both range from point mutations to whole gene dele-
tions and chromosome rearrangements, and spread
across the entire length of the genes.
Several reasons are being postulated for the lower de-
tection rate of EP300 mutations: a lower mutation rate;
underdiagnosis at similar mutation rates following the
generally milder phenotype in cases of RSTS with EP300
mutation; or misdiagnosis in cases with severe pheno-
type resembling other syndromes with congenital mal-
formations such as Cornelia de Lange syndrome (CdLS)
which interestingly is caused by alterations in other
chromatin associated proteins [1, 9, 13, 17].
In this case report we describe an inherited RSTS case
associated with a novel EP300 mutation, representing
the first familial case found in Spain.
Case presentation
Proband was a 9-year-old girl, referred to the Genetics
Clinic by the neuropediatrician who had been following
her for mild learning difficulties. RSTS was suspected
after seeing her mother, who also had learning difficul-
ties and had short broad thumbs. Our patient was born
at term via Cesarean section (pelvi-fetal disproportion)
after an uneventful pregnancy. Both, weight and length
at birth were low: 2.3 kg (−2.38 SD) and 46 cm (−2.07
SD), respectively. Occipitofrontal head circumference
(OHC) at birth was not recorded. The girl’s development
was within normal range in the first years of life but in-
creasing learning difficulties were noted at primary
school. She is at her expected grade with educational
support. On physical examination the proband’s weight
was 21.4 kg (−1.74 SD), her length 119 cm (−3.15 SD on
Spain 2000 growth chart), and her OHC 48.7 cm (−2.9
SD). She had a thickened and low hanging columella.
Her hands and feet (thumbs and halluces) were quite
normal (Fig. 1. Phenotype table (Additional file 1)).
The mother (42 y.o.) had short stature (141 cm (−3.87
SD)) and proportionately small OHC (49 cm (−4 SD)).
She had struggled at school but managed to get the
Secondary School Certificate. Nowadays she is working
as a check-out in a supermarket. Her general health is
good. She is a single mother of two children: the pro-
band and a healthy 7 year old boy. She had slightly pos-
teriorly rotated ears, a prominent nose with high nasal
bridge, low hanging columella, and talon cusp at an upper
incisor. Her thumbs were short and broad but not angu-
lated and her halluces were normal (Fig. 1. Phenotype
table (Additional file 1)). Proband’s maternal aunt and
grandmother also had short stature and proportionate
OHC but normal intelligence and normal hands and feet.
The grandmother’s length was 142.1 cm (−3.5 SD) and
her OHC 52.5 cm (−1.9 SD). Maternal grandfather died
aged 50 from liver disease.
Previous assessments of the proband included a hand
X-ray for bone age, which was according to chronological
age, and endocrine tests with normal levels of growth hor-
mone in two stimulation tests. A brain MRI scan showed
a pineal cyst (9 × 9 × 5 mm) and no other anomalies.
Clinical data, samples and photographs were obtained
after written informed consent. This work has been ap-
proved by the Committee for Ethics in Clinical Research
in La Rioja (CEICLAR).
Blood samples from the proband, her mother and her
grandmother were collected in EDTA tubes. DNA was
extracted using QIAamp DNA Mini Kit (QIAGEN) fol-
lowing the manufacture’s protocol. MLPA of CREBBP
and EP300 was performed (P313 and P333 Kit, MRC-
Holland). Panel-based next generation sequencing
(NGS) of CREBBP and EP300 genes was carried out.
Briefly, libraries encompassing exons and introns of
CREBBP and EP300 genes were prepared using the
SureSelectXT2 Custom kit (Agilent) and sequenced to
generate 150 bp single reads. The resulting reads were
mapped to the human genome hg19 using BWA (ver-
sion 0.7.12). Sequence variants were called using the
Genome Analysis Toolkit (GATK) version 3.3 and called
variants were annotated with Annovar. ExAC browser of
Broad Institute, 1000 Genomes database and dbSNP138,
as well as, the Human Gene Mutation Database
(HGMD), Leiden Open Variation Database (LOVD) and
ClinVar databases were checked to assess the presence/
absence of detected alterations in variations repositories.
Results and discussion
MLPA did not reveal any deletion within the CREBBP or
EP300 genes. Only one variant was identified in the panel-
based NGS of CREBBP and EP300 genes: a heterozygous
mutation in exon 31 of the EP300 gene (RefSeq
NM_001429.3: c.7222_7223del; p.(Gln2408Glufs*39)). As
in the proband, this variant was also found in the hetero-
zygous state in the mother as is shown by the number of
reads (238 reads with deletion of a total of 486, for the
proband; and 219/485 for her mother). This finding was
confirmed by Sanger sequencing. This variant was not
found in 100 healthy controls and it is not present in
1000G, ExAC and dbSNP, indicating that this variant
is not common in population. To the best of our
knowledge this variant has not been previously de-
scribed, and it is not included in ClinVar, HGMD or
LOVD. The variant has now been included in ClinVar
database (SCV000266471) and in LOVD (individual
#00064625). The deletion generates a frameshift that
leads to loss of the original stop codon and results in
a prolonged protein 31 aminoacids longer. This
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variation is considered to be pathogenic/likely patho-
genic, according to ACMG interpretation: null variant
in a gene where LOF is a known mechanism of dis-
ease, absent in population databases, protein length
changing variant, and patient’s phenotype highly spe-
cific for gene [12].
According to the literature, point mutations are wide-
spread along the whole EP300 gene without any remark-
able hot spot, being frameshift mutations the most
common found, as is our case [10, 14]. Likewise,
genotype-phenotype correlations indicated that patients
with larger deletions did not always have a more severe
phenotype than those with smaller deletions or point
mutations. On the other hand, it seems that mutations
that do not alter HAT domain could explain non-
classical RSTS cases [3, 18]. In this sense, the location of
the frameshift deletion described in this report, very
close to the 5′-end of EP300 gene, not affecting HAT
domain and PHD finger, could explain the mild pheno-
type and the well-preserved intelligence.
Addressing the lower frequency of EP300 mutations
(EP300 mutations are 10 times less frequent than
CREBBP mutations), it may be possible that EP300 gene
had a lower mutation rate than CREBBP, nevertheless,
many more polymorphisms have been found in this
gene, including some that lead to amino acid changes
[13]. Hence, EP300 mutations might account for a
higher frequency of RSTS patients than previously
thought. However, because of phenotypic variability such
patients are not ascertained and not studied.
Fig. 1 Images showing classical RSTS features of patient including thickened and low hanging columella (a, b), and detail of mother’s talon cusp
at an upper incisor (c). Photographs showing normal thumbs and halluces of the proband (d, e), short and broad but not angulated thumbs of
her mother (f, g) and her grandmother (h, i)
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Molecular analysis was performed in mother and
grandmother and it was positive in the mother and
negative in the grandmother, confirming the inherited
character of this mutation, suggesting three possible op-
tions: 1) the mutation appeared de novo in the mother
and was passed on to her daughter, 2) the grandmother
could have germline mosaicism, that could not be cor-
roborated or 3) the grandfather, who presented broad
thumbs, could also be a carrier of the mutation.
Thereby, despite the inherited confirmation of this RSTS
case, it has not been possible to determine the exact
point where the mutation appeared.
Familial RSTS is extremely rare, in this regards, be-
tween 1000 and 2000 cases of RSTS have been reported
but only 11 cases of familial RSTS have been described
[3–6, 8, 11], and are most likely linked to somatic mosai-
cism. Moreover, in all the cases in which the molecular
cause was determined, it was associated with the
CREBBP gene. Recently, Tamhankar et al., reported a
patient with mutation in EP300 gene inherited from a
healthy mother [15]. Also Negri et al., and Wincent
et al., [10, 16] found a missense variation in both, a
patient and his healthy mother and father, respect-
ively, but both were considered as not pathogenic. Al-
though Tamhankar et al. suggested the possibility of
low penetrance, these variants should be considered
not pathogenic, since they have been detected in
healthy parents. Moreover, only one EP300 missense
mutation has been previously observed in RSTS pa-
tients [10], indicating that this type of change is not
probable as causative of RSTS.
Affected children tend to have more pronounced fea-
tures than their affected parent in familial RSTS [3].
Conversely, in our case it was the mother who showed
the characteristic thumbs, facial features and dental
anomalies, giving rise to the suspicion of RSTS diagno-
sis. On the other hand, the familial short stature with
proportionately small HC turned out not to segregate
with the EP300 mutation and may therefore be associ-
ated with other genetic factors not studied.
This study broadens the number of phenotypic
EP300-patients described to 24 providing additional
knowledge about the phenotype of these RSTS-2
cases. In general, this cohort presents mild presenta-
tion of the phenotype, and also few phenotypic pecu-
liarities, what is attested by the age at diagnosis,
usually higher in EP300 patients [9, 10, 14]. Our ob-
servations are in accordance with this, since the pro-
band was diagnosed at the age of 9, and her mother
was not diagnosed, until this study.
According to the literature, these patients usually
present a mild presentation of the syndrome. It is fre-
quently reported in these RSTS-2 patients classic facial
RSTS features (prominent nose with low-hanging nasal
septum, downward slanting palpebral fissures, etc.); vari-
able degree of intellectual disability, ranging from mild
to moderate (no patient has a severe impairment); mild
skeletal phenotype, even if there are cases described with
normal thumbs and toes, it is common to find broad
thumbs and big toes although with no radial deviation of
them [1, 10, 16]. In our case, mother and proband
showed mild learning difficulties, but the mother was
able to lead a normal life. Both showed facial character-
istics of RSTS although they were more evident in the
mother. Also, the mother had broad but not angulated
thumbs, whereas the child had normal thumbs and
halluces.
Conclusion
In summary, this study presents the first case of inher-
ited EP300-RSTS. This report underscores the possible
lack of diagnosis in these patients with non-classic pre-
sentations, as is the case of patient’s mother. Therefore,
variable clinical expression exists in RSTS and normal
functioning individuals may carry disease-associated mu-
tations, even in a non-mosaic state. These findings have
implications for genetic counselling and we would rec-
ommend molecular testing of apparently healthy par-
ents, and in the case of inherited mutations, of all adult
first degree relatives at risk. Thus, it is important to
highlight that since most individuals with RSTS due to
EP300 mutation are mildly affected, this entity is likely
underdiagnosed and special attention should be paid.
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mother. (XLS 26 kb)
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